Related Experiment Videos
Sequential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice
Insights
Amoxicillin/clavulanate effectively treats pediatric bacterial infections. This antibiotic combination demonstrated safety and efficacy in hospitalized children across various infection types.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Bacteriology
Background:
- Bacterial infections are common in children, necessitating effective and safe treatment options.
- Amoxicillin/clavulanate is a widely used antibiotic combination for various infections.
Purpose of the Study:
- To evaluate the efficacy and safety of amoxicillin/clavulanate therapy in hospitalized pediatric patients.
- To assess treatment outcomes for diverse bacterial infections in children.
Main Methods:
- A study involving 71 hospitalized pediatric patients (1 month to 16 years) treated with intravenous and sequential intravenous-oral amoxicillin/clavulanate.
- Infections included respiratory, urinary tract, and skin/soft tissue infections of moderate to severe intensity.
Main Results:
- All 71 patients achieved clinical cure with prompt response to amoxicillin/clavulanate therapy.
- Bacterial pathogens were identified in 37% of cases.
- Adverse effects were generally mild, including phlebitis (6%), gastrointestinal issues (6%), and rash (4%).
Conclusions:
- Amoxicillin/clavulanate is an effective and safe therapeutic option for pediatric bacterial infections.
- The antibiotic combination is suitable for treating respiratory tract, urinary tract, skin, and soft tissue infections in children.
Abstract:
The efficacy and safety of intravenous and sequential intravenous-oral clavulanate-potentiated amoxycillin therapy was evaluated in 71 hospitalized paediatric patients, one month to 16 years of age. The infections treated included peritonsillar abscess (2 patients), purulent tracheitis (1), acute epiglottitis (24), pneumonia (31), pansinusitis (4), mastoiditis (1), cellulitis (4), lymphadenitis (2) and pyelonephritis (2). The severity of disease was rated as moderate in 31 patients (44%), and as severe in 40 (56%). Bacterial pathogens could be cultured in 26 cases (37%). The response to therapy was prompt and followed by clinical cure in each patient. Adverse drug effects included phlebitis (in 6%), mild gastrointestinal complaints (6%), rash (4%) and transient neutropenia and elevation of transaminases (one case each). It is concluded that amoxycillin/clavulanate is effective and safe treatment for bacterial infections of the respiratory tract, urinary tract, skin or soft tissues in children.